Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial
Nephrology Dialysis Transplantation · 30.06.2025 · 40 (7) · 1384-1395
DOI: 10.1093/ndt/gfae282 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 29.11.2024. Verfasst von Aylin Akifova und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Cell-Free Nucleic Acids, Tissue Donors. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oncocyte.
Abstract (Originalsprache)
Background
Donor-derived cell-free DNA (dd-cfDNA) shows good diagnostic performance for the detection of antibody-mediated rejection (AMR) in kidney transplant recipients (KTR). However, the clinical benefits of dd-cfDNA monitoring need to be established. Early diagnosis of AMR at potentially reversible stages may be increasingly important due to emerging treatment options for AMR. We hypothesized that monitoring dd-cfDNA in KTR with de novo donor-specific anti-HLA antibodies (dnDSA) and performing kidney biopsy in case of increased dd-cfDNA may reduce time to AMR diagnosis in comparison with clinical indication biopsy.
Methods
In this diagnostic, single-center, open-label, randomized clinical trial, we assigned 40 KTR with prevalent dnDSA and estimated glomerular filtration rate ≥20 mL/min/1.73 m2, but without previous biopsy-proven AMR, to either dd-cfDNA-guided biopsy (intervention group) or clinician-guided biopsy (control group) over a 12-month period. In both groups, dd-cfDNA was assessed at inclusion and 1, 3, 6, 9 and 12 months. In the intervention group, dd-cfDNA >50 copies/mL indicated a biopsy. Biopsies for clinical indication could be performed at any point during the study period in both groups. A protocol biopsy was scheduled after 12 months for patients without dd-cfDNA-guided biopsy or clinical indication biopsy until study completion. The primary endpoint was time from study inclusion to diagnosis of active or chronic active AMR.
Results
Thirty-nine of 40 patients had functioning grafts at study completion. From these, 26 patients underwent biopsy, 13 in each group. AMR was diagnosed earlier in the intervention group than in the control group [median 2.8 months, interquartile range (IQR) 1.7–5.3 vs median 14.5 months, IQR 13.3–16.7, P = .003]. Longitudinal dd-cfDNA monitoring had 77% positive predictive value and 85% negative predictive value for AMR.
Conclusions
Dd-cfDNA-guided biopsy in KTR with prevalent dnDSA can reduce the time to AMR diagnosis and hereby expedite therapy initiation.
Trial registration
ClinicalTrials.gov, NCT04897438.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Nephropathology, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
- Department of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany.
- Chronix Biomedical GmbH, Göttingen, Germany.
- Valdecilla Biomedical Research Institute (IDIVAL), Santander, Spain.
- Centre for Tumor Medicine, Histocompatibility & Immunogenetics Laboratory, Charité - Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Aylin Akifova, Klemens Budde, Johannes Waiser, Kai-Uwe Eckardt, Covadonga López Del Moral
Förderung
- Oncocyte
Zitieren
APA
Akifova, A., Budde, K., Amann, K., Buettner-Herold, M., Choi, M., Oellerich, M., Beck, J., Bornemann-Kolatzki, K., Schütz, E., Bachmann, F., Halleck, F., von Hoerschelmann, E., Koch, N., Schrezenmeier, E., Seelow, E., Waiser, J., Zukunft, B., Eckardt, K. U., Halbritter, J., …, & Osmanodja, B. (2025). Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial. Nephrology Dialysis Transplantation, 40(7), 1384-1395. https://doi.org/10.1093/ndt/gfae282
Vancouver
Akifova A, Budde K, Amann K, Buettner-Herold M, Choi M, Oellerich M, et al. Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial. Nephrology Dialysis Transplantation. 2025;40(7):1384-1395. doi:10.1093/ndt/gfae282
BibTeX
@article{Akifova2025,
author = {Akifova, Aylin and Budde, Klemens and Amann, Kerstin and Buettner-Herold, Maike and Choi, Mira and Oellerich, Michael and Beck, Julia and Bornemann-Kolatzki, Kirsten and Schütz, Ekkehard and Bachmann, Friederike and Halleck, Fabian and von Hoerschelmann, Ellen and Koch, Nadine and Schrezenmeier, Eva and Seelow, Evelyn and Waiser, Johannes and Zukunft, Bianca and Eckardt, Kai-Uwe and Halbritter, Jan and Kettritz, Ralph and Del Moral, Covadonga López and Lachmann, Nils and Stauch, Diana and Niemann, Matthias and Schmidt, Danilo and Halloran, Philip F and Osmanodja, Bilgin},
title = {Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {7},
pages = {1384--1395},
doi = {10.1093/ndt/gfae282}
}
EUVIMED